VCMC ED / INPATIENT

VCMC ED/IP ANTIBIOGRAM 2024 GRAM NEGATIVE % SUSCEPTIBLE (Of Isolates tested)	# of isolates tested	Amp/Sulbactam	Cefazolin*	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin	Meropenem	Nitrofurantoin*	Pip/Tazobactam	Tobramycin	Trimethoprim/Sulfa
E. coli	573	60	84	90	87	87	75	100	88	(100)	97	95	88	88
Enterobacter cloacae	33	0	0	91	N	N	97	91	100	(100)	33	84	100	100
Klebsiella aerogenes	17	0	0	100	N	N	100	100	100	(100)	6	76	100	100
Klebsiella pneumoniae	117	77	85	90	85	76	100	97	91	(100)	21	95	88	81
Proteus mirabilis	51	82	90	96	90	90	82	100	90	(100)	0	100	92	80
Pseudomonas aeruginosa	75	0	0	100	100	0	83	0	99	96	0	88	97	0
Serratia marcescens	12	N	N	100	100	83	83	92	100	N	0	(100)	92	83

* Nitrofurantoin and Cefazolin: use only for the treatment of uncomplicated cystitis.
Cefazolin results predict results for oral cephalexin and cefuroxime when used to treat uncomplicated cystitis.
X: not tested
N: not recommended
( ): presumed susceptibility

15 % of *E. coli* are Extended Spectrum Beta Lactamase (ESBL) Producing.

15 % of *Klebsiella pneumoniae* are ESBL producing.

VCMC ED/IP ANTIBIOGRAM 2024 GRAM POSITIVE % SUSCEPTIBLE (of Isolates tested)	# of isolates tested	Amp/Sulbactam	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin	Levofloxacin	Oxacillin	Penicillin	Doxycycline	Trimethoprim/Sulfa	Vancomycin
Staphylococcus aureus (MSSA)	294	N	0	(100)	X	X	N	94	100	N	100	0	100	94	100
Staphylococcus aureus (MRSA)	122	0	0	0	0	0	N	95	100	N	0	0	94	86	100
Staphylococcus epidermidis	29	N	0	X	X	X	N	54	100	N	29	0	86	N	100
Enterococcus faecalis	182	X	98	0	0	0	N	0	100	N	X	X	20	0	98
Enterococcus faecium	37	X	31	0	0	0	N	0	X	N	X	X	40	0	51

X: not tested
N: not recommended
( ): presumed susceptibility
(m): susceptibility results for Ceftriaxone and Penicillin if treating meningitis. If not treating meningitis, % susceptibility for Ceftriaxone and Penicillin is 100%.
29% of *Staphylococcus aureus* are Methicillin Resistant (MRSA).

71% of *Staphylococcus aureus* are Methicillin Susceptible (MSSA).

Data from isolate totals < 30 may be statistically unreliable.

VCMC/SPH Antimicrobial Stewardship Committee 02/20/2025

Santa Paula Hospital ED / Inpatient

SPH ED/IP ANTIBIOGRAM 2024 GRAM NEGATIVE % SUSCEPTIBLE (of Isolates tested)	# of isolates tested	Amp/Sulbactam	Cefazolin*	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin	Meropenem	Nitrofurantoin*	Pip/Tazobactam	Tobramycin	Trimethoprim/Sulfa
E. coli	204	61	82	88	83	83	72	100	82	(100)	98	96	83	66
Klebsiella pneumoniae	29	79	79	86	79	79	81	96	93	(100)	14	93	83	82
Proteus mirabilis	27	85	85	100	85	93	81	96	96	(100)	0	100	100	81
Pseudomonas aeruginosa	22	0	0	81	86	0	77	0	95	86	0	74	100	0

*Nitrofurantoin and cefazolin: use only for the treatment of uncomplicated cystitis.

Cefazolin results predict results for oral cephalexin and cefuroxime when used to treat uncomplicated cystitis.

X: not tested

N: not recommended

( ): presumed susceptibility

19% of *E. coli* are Extended Spectrum Beta Lactamase (ESBL) Producing.

17% of *Klebsiella pneumoniae.* are ESBL Producing.

SPH ED/IP ANTIBIOGRAM 2024 GRAM POSITIVE % SUSCEPTIBLE (of Isolates tested)	# of isolates tested	Amp/Sulbactam	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin	Erythromycin	Levofloxacin	Oxacillin	Penicillin	Doxycycline	Trimethoprim/Sulfa	Vancomycin
Staphylococcus aureus (MSSA)	39	N	X	(100)	X	X	N	85	100	N	N	100	0	95	85	100
Staphylococcus aureus (MRSA)	23	0	X	0	0	0	N	86	100	N	N	0	0	100	91	100
Enterococcus faecalis	34	X	94	0	0	0	N	0	96	0	N	X	X	15	0	98

X: not tested

N: not recommended

( ): presumed susceptibility

37% of *Staphylococcus aureus* are Methicillin Resistant (MRSA).

63% of *Staphylococcus aureus* are Methicillin Susceptible (MSSA).

Streptococcus pneumoniae: too few isolates to report.

Data from isolate totals < 30 may be statistically unreliable.

VCMC/SPH Antimicrobial Stewardship Committee 2/20/2025.